Bimodal fluorescence/129Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer

Gaëlle Milanole; Bo Gao; Audrey Paoletti; Grégory Pieters; Christophe Dugave; Eric Deutsch; Sofia Rivera; Frédéric Law; Jean Luc Perfettini; Emilie Mari; Estelle Léonce; Céline Boutin; Patrick Berthault; Hervé Volland; François Fenaille; Thierry Brotin; Bernard Rousseau

doi:10.1016/j.bmc.2017.11.002

Bimodal fluorescence/¹²⁹Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer

Gaëlle Milanole, Bo Gao, Audrey Paoletti, Grégory Pieters, Christophe Dugave, Eric Deutsch, Sofia Rivera, Frédéric Law, Jean Luc Perfettini, Emilie Mari, Estelle Léonce, Céline Boutin, Patrick Berthault, Hervé Volland, François Fenaille, Thierry Brotin, Bernard Rousseau

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Although Non-Small Cell Lung Cancer (NSCLC) is one of the main causes of cancer death, very little improvement has been made in the last decades regarding diagnosis and outcomes. In this study, a bimodal fluorescence/¹²⁹Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. This biosensor shows high selectivity for the EGFR, and a biological activity similar to that of the antibody. It is detected with high specificity and high sensitivity (sub-nanomolar range) through hyperpolarized ¹²⁹Xe NMR. This promising system should find important applications for theranostic use.

Original language	English
Pages (from-to)	6653-6660
Number of pages	8
Journal	Bioorganic and Medicinal Chemistry
Volume	25
Issue number	24
DOIs	https://doi.org/10.1016/j.bmc.2017.11.002
Publication status	Published - 15 Dec 2017

Keywords

Biosensor
Cetuximab
EGFR
Hyperpolarized xenon
NMR

Access to Document

10.1016/j.bmc.2017.11.002

Cite this

Milanole, G., Gao, B., Paoletti, A., Pieters, G., Dugave, C., Deutsch, E., Rivera, S., Law, F., Perfettini, J. L., Mari, E., Léonce, E., Boutin, C., Berthault, P., Volland, H., Fenaille, F., Brotin, T., & Rousseau, B. (2017). Bimodal fluorescence/¹²⁹Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer. Bioorganic and Medicinal Chemistry, 25(24), 6653-6660. https://doi.org/10.1016/j.bmc.2017.11.002

@article{042f70ed499e4f0f96f0eccb1d33bc24,

title = "Bimodal fluorescence/129Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer",

abstract = "Although Non-Small Cell Lung Cancer (NSCLC) is one of the main causes of cancer death, very little improvement has been made in the last decades regarding diagnosis and outcomes. In this study, a bimodal fluorescence/129Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. This biosensor shows high selectivity for the EGFR, and a biological activity similar to that of the antibody. It is detected with high specificity and high sensitivity (sub-nanomolar range) through hyperpolarized 129Xe NMR. This promising system should find important applications for theranostic use.",

keywords = "Biosensor, Cetuximab, EGFR, Hyperpolarized xenon, NMR",

author = "Ga{\"e}lle Milanole and Bo Gao and Audrey Paoletti and Gr{\'e}gory Pieters and Christophe Dugave and Eric Deutsch and Sofia Rivera and Fr{\'e}d{\'e}ric Law and Perfettini, {Jean Luc} and Emilie Mari and Estelle L{\'e}once and C{\'e}line Boutin and Patrick Berthault and Herv{\'e} Volland and Fran{\c c}ois Fenaille and Thierry Brotin and Bernard Rousseau",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = dec,

day = "15",

doi = "10.1016/j.bmc.2017.11.002",

language = "English",

volume = "25",

pages = "6653--6660",

journal = "Bioorganic and Medicinal Chemistry",

issn = "0968-0896",

number = "24",

}

Milanole, G, Gao, B, Paoletti, A, Pieters, G, Dugave, C, Deutsch, E, Rivera, S, Law, F, Perfettini, JL, Mari, E, Léonce, E, Boutin, C, Berthault, P, Volland, H, Fenaille, F, Brotin, T & Rousseau, B 2017, 'Bimodal fluorescence/¹²⁹Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer', Bioorganic and Medicinal Chemistry, vol. 25, no. 24, pp. 6653-6660. https://doi.org/10.1016/j.bmc.2017.11.002

TY - JOUR

T1 - Bimodal fluorescence/129Xe NMR probe for molecular imaging and biological inhibition of EGFR in Non-Small Cell Lung Cancer

AU - Milanole, Gaëlle

AU - Gao, Bo

AU - Paoletti, Audrey

AU - Pieters, Grégory

AU - Dugave, Christophe

AU - Deutsch, Eric

AU - Rivera, Sofia

AU - Law, Frédéric

AU - Perfettini, Jean Luc

AU - Mari, Emilie

AU - Léonce, Estelle

AU - Boutin, Céline

AU - Berthault, Patrick

AU - Volland, Hervé

AU - Fenaille, François

AU - Brotin, Thierry

AU - Rousseau, Bernard

PY - 2017/12/15

Y1 - 2017/12/15

N2 - Although Non-Small Cell Lung Cancer (NSCLC) is one of the main causes of cancer death, very little improvement has been made in the last decades regarding diagnosis and outcomes. In this study, a bimodal fluorescence/129Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. This biosensor shows high selectivity for the EGFR, and a biological activity similar to that of the antibody. It is detected with high specificity and high sensitivity (sub-nanomolar range) through hyperpolarized 129Xe NMR. This promising system should find important applications for theranostic use.

AB - Although Non-Small Cell Lung Cancer (NSCLC) is one of the main causes of cancer death, very little improvement has been made in the last decades regarding diagnosis and outcomes. In this study, a bimodal fluorescence/129Xe NMR probe containing a xenon host, a fluorescent moiety and a therapeutic antibody has been designed to target the Epidermal Growth Factor Receptors (EGFR) overexpressed in cancer cells. This biosensor shows high selectivity for the EGFR, and a biological activity similar to that of the antibody. It is detected with high specificity and high sensitivity (sub-nanomolar range) through hyperpolarized 129Xe NMR. This promising system should find important applications for theranostic use.

KW - Biosensor

KW - Cetuximab

KW - EGFR

KW - Hyperpolarized xenon

KW - NMR

UR - http://www.scopus.com/inward/record.url?scp=85034816930&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2017.11.002

DO - 10.1016/j.bmc.2017.11.002

M3 - Article

C2 - 29150078

AN - SCOPUS:85034816930

SN - 0968-0896

VL - 25

SP - 6653

EP - 6660

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

IS - 24

ER -